Loading organizations...
§ Private Profile · 121 Mount Vernon St, Boston, Massachusetts, 02108, United States
ScienceIO is a technology company.
ScienceIO builds a sophisticated biomedical language platform designed to transform complex, unstructured medical text into actionable data and insights. Leveraging an advanced AI approach to machine learning, the company's core technology boasts the ability to recognize an unprecedented nine million distinct medical concepts. This capability allows the platform to extract valuable information from clinical narratives and various healthcare documents, making it accessible and usable for a wide range of applications within the healthcare ecosystem.
The company was founded in 2021 by Will Manidis, who serves as CEO, and Gaurav Kaushik, its President. Their foundational insight stemmed from the pervasive challenge of unstructured data within healthcare, recognizing an urgent need to address this data problem to accelerate innovation across the industry. Their combined expertise drives the development of a platform crucial for advancing data utilization in medicine.
Healthcare professionals and organizations utilize ScienceIO's platform to enhance operational efficiency and improve patient care. The company’s overarching vision is to empower its users with secure and responsible artificial intelligence, enabling them to streamline workflows, refine decision-making processes, and ultimately achieve superior patient outcomes. ScienceIO remains committed to its mission of accelerating healthcare innovation through intelligent data solutions.
ScienceIO has raised $8.0M across 1 funding round.
ScienceIO has raised $8.0M in total across 1 funding round.
ScienceIO is a healthcare AI company founded in 2019 that builds an AI platform to transform unstructured medical text into structured, enriched data, enabling healthcare providers, payers, and organizations to organize patient data, improve workflows, and deliver better outcomes.[1][2][3][5] Its core product, Structure, uses machine learning via a single API call to identify and map over 9 million medical concepts—including conditions, procedures, devices, therapies, and biomarkers—while handling protected health information and supporting use cases like anonymization, record linkage, summarization, and predictive analytics.[1][6][7] ScienceIO serves the healthcare industry, primarily providers and payers, solving the problem of vast, unusable unstructured data (which comprises the majority of healthcare records) by making it accessible and actionable without compromising privacy.[2][3][5] The company raised $8.1M in seed funding, emerged from stealth in 2021, and was acquired by Veradigm in February 2024 for $140M, accelerating its integration into larger healthcare data ecosystems.[1][3][4]
ScienceIO was co-founded in 2019 by Will Manidis (CEO, Thiel Fellow, former managing partner at Dorm Room Fund) and Gaurav Kaushik (President/COO, PhD, former lead of real-world data products at Foundation Medicine), who identified healthcare's core challenge: the vast majority of patient data remains unstructured and unutilized, hindering decision-making.[3][5][6] Headquartered initially in Boston (with some sources noting New York ties), the idea emerged from their expertise in data science and investing, aiming to use AI to contextualize and link biomedical terms across silos.[3][5] Key early traction included emerging from stealth in October 2021 with $8M seed funding from technology and life sciences investors like Section 32, participation in Mayo Clinic's AI accelerator in 2022, and recognition as a Challenger in CB Insights' Healthcare AI model developers ESP matrix alongside Amazon and Google.[1][4][5] This momentum led to its acquisition by Veradigm in 2024.[1][4]
ScienceIO rides the explosive growth of generative AI and foundation models in healthcare, where unstructured data silos block insights from 400M+ patient records, amid trends like revenue cycle management, medical imaging, and clinical decision support.[1][4] Its timing aligns perfectly with post-2023 AI adoption surges, including digital health M&A where every second deal involves AI, and the need for de-identified data to train proprietary LLMs on massive datasets.[1][4] Market forces favoring it include regulatory pushes for data interoperability (e.g., via APIs), payer-provider consolidation, and Veradigm's 200M+ patient data asset, amplifying ScienceIO's reach.[3][4] By digitizing global healthcare data for software engineers, it influences the ecosystem by accelerating innovation, reducing manual processing, and enabling AI centers of excellence that span providers, payers, and life sciences.[2][4][6]
Post-acquisition by Veradigm, ScienceIO's platform will fuel proprietary LLMs on vast datasets, establishing an AI center of excellence to enhance insights across business units and drive market-leading capabilities in healthcare analytics.[3][4] Trends like multimodal AI, real-world evidence generation, and equitable data access will shape its path, potentially expanding to global markets and new modalities beyond text.[1][2] Its influence may evolve from a standalone extractor to a foundational layer in integrated health platforms, empowering faster patient outcomes amid AI-healthcare convergence—transforming fragmented data from a burden into healthcare's ultimate accelerator, as envisioned from its 2019 origins.[5][6]
ScienceIO has raised $8.0M in total across 1 funding round.
ScienceIO's investors include Will Manidis, 1517 Fund, 75 & Sunny, 7percent Ventures, Abstract Ventures, AirAngels, Alchemy Ventures, Alt Capital, Ambush Capital, AME Cloud Ventures, Andreessen Horowitz, Angel investor.
ScienceIO has raised $8.0M across 1 funding round. Most recently, it raised $8.0M Seed in October 2021.